SEARCH:   Advanced

Blood, 1 May 2006, Vol. 107, No. 9, pp. 3787-3794. Prepublished online as a Blood First Edition Paper on January 17, 2006; DOI 10.1182/blood-2005-11-4495. This Article Full Text (PDF) All Versions of this Article: 2005-11-4495v1 107/9/3787    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chorny, A. Articles by Delgado, M. Search for Related Content PubMed PubMed Citation Articles by Chorny, A. Articles by Delgado, M. Related Collections Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 14, 2005 Accepted December 20, 2005 Vasoactive intestinal peptide induces regulatory dendritic cells that can prevent acute graft-versus-host disease while maintain graft-versus-tumor Alejo Chorny, Elena Gonzalez-Rey, Amelia Fernandez-Martin, Doina Ganea, and Mario Delgado* Instituto Parasitologia y Biomedicina, CSIC, Granada, Granada, Spain Dept of Biological Sciences, Rutgers University, Newark, NJ, USA * Corresponding author; email: mdelgado{at}ipb.csic.es. Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic bone marrow transplantation (BMT) for the treatment of leukemia and other immunogenetic disorders. The use of tolerogenic dendritic cells (DCs) that induce the generation/activation of regulatory T cells (Tr) for the treatment of acute GVHD following allogeneic BMT has been recently established. Therefore, the identification of factors that contribute to the development of tolerogenic DCs is highly relevant. We report on the use of the known immunosuppressive neuropeptide, the vasoactive intestinal peptide (VIP), as a new approach to induce tolerogenic DCs with the capacity to prevent acute GVHD. DCs differentiated in the presence of VIP impair allogeneic haplotype-specific responses of donor CD4+ cells in transplanted mice by inducing the generation of Tr in the graft. VIP-induced tolerogenic DCs did not abrogate the graft-versus-leukemia response presumably by not affecting the cytotoxicity of transplanted T cells against the leukemic cells. Therefore, the inclusion of VIP-induced tolerogenic DC in future therapeutic regimens may minimize the dependence on non-specific immunosuppressive drugs used currently as anti-rejection therapy, and facilitate the successful transplantation from mismatched donors, by reducing the deleterious consequences of acute GVHD and extending the applicability of BMT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Dendritic cells get VIP treatment Edmund K. Waller Blood 2006 107: 3423-3424. [Full Text] [PDF] Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells Elena Gonzalez-Rey, Alejo Chorny, Amelia Fernandez-Martin, Doina Ganea, and Mario Delgado Blood 2006 107: 3632-3638. [Abstract] [Full Text] [PDF] This article has been cited by other articles: D. Pozo, P. Anderson, and E. Gonzalez-Rey Induction of Alloantigen-Specific Human T Regulatory Cells by Vasoactive Intestinal Peptide J. Immunol., October 1, 2009; 183(7): 4346 - 4359. [Abstract] [Full Text] [PDF] A. E. Anderson, D. J. Swan, B. L. Sayers, R. A. Harry, A. M. Patterson, A. von Delwig, J. H. Robinson, J. D. Isaacs, and C. M. U. Hilkens LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells J. Leukoc. Biol., February 1, 2009; 85(2): 243 - 250. [Abstract] [Full Text] [PDF] V. W. S. Lee, Y. M. Wang, Y. P. Wang, D. Zheng, T. Polhill, Q. Cao, H. Wu, I. E. Alexander, S. I. Alexander, and D. C. H. Harris Regulatory immune cells in kidney disease Am J Physiol Renal Physiol, August 1, 2008; 295(2): F335 - F342. [Abstract] [Full Text] [PDF] A. E. Anderson, B. L. Sayers, M. A. Haniffa, D. J. Swan, J. Diboll, X.-N. Wang, J. D. Isaacs, and C. M. U. Hilkens Differential regulation of naive and memory CD4+ T cells by alternatively activated dendritic cells J. Leukoc. Biol., July 1, 2008; 84(1): 124 - 133. [Abstract] [Full Text] [PDF] S. Fujita, Y. Sato, K. Sato, K. Eizumi, T. Fukaya, M. Kubo, N. Yamashita, and K. Sato Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease mediated through CD4+CD25+Foxp3+ regulatory T cells Blood, November 15, 2007; 110(10): 3793 - 3803. [Abstract] [Full Text] [PDF] D. Fabricius, M. S. O'Dorisio, S. Blackwell, and B. Jahrsdorfer Human Plasmacytoid Dendritic Cell Function: Inhibition of IFN-{alpha} Secretion and Modulation of Immune Phenotype by Vasoactive Intestinal Peptide J. Immunol., November 1, 2006; 177(9): 5920 - 5927. [Abstract] [Full Text] [PDF] S. Rutella, S. Danese, and G. Leone Tolerogenic dendritic cells: cytokine modulation comes of age Blood, September 1, 2006; 108(5): 1435 - 1440. [Abstract] [Full Text] [PDF] E. K. Waller A tale of two T cells: suppressor CD8 T cells recalled to life Blood, June 1, 2006; 107(11): 4203 - 4204. [Full Text] [PDF] E. Gonzalez-Rey, A. Chorny, A. Fernandez-Martin, D. Ganea, and M. Delgado Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells Blood, May 1, 2006; 107(9): 3632 - 3638. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020